Breaking News

Orexo, AZ in Respiratory Research Pact

January 25, 2013

AZ takes on preclinical development of OX-CLI program

Orexo AB has entered into an agreement with AstraZeneca for its OX-CLI preclinical program for the potential treatment of respiratory diseases. AZ has been granted rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AZ also has an option to acquire the compounds, subject to a full asset transfer agreement, under which Orexo will receive development milestones and royalties on future revenues. Financial terms were not disclosed.
 
“Our OX-CLI program is a promising R&D project, which has potential to improve the treatment of respiratory diseases for millions of patients. AstraZeneca, a leading global company within the inflammatory and respiratory area, is the optimal partner for OX-CLI and we look forward to see the project advancing,” said chief executive officer Anders Lundström.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent